公开(公告)号：US20210070869A1

公开(公告)日：2021-03-11

申请号：US17046199

申请日：2019-04-10

Applicant: GENMAB A/S

Inventor： Maarten JANMAAT ,  Esther BREIJ ,  Ulf FORSSMANN ,  Tahamtan AHMADI ,  Julia BOSHUIZEN ,  Daniel PEEPER ,  Nora PENCHEVA

IPC: C07K16/28 ,  A61K47/68 ,  A61P35/00

Abstract: The disclosure relates to anti-AXL antibodies, immunoconjugates, and compositions for treatment of cancer, which is resistant to or is predicted to be or become resistant to treatment with a programmed cell death-1/programmed cell death-1 ligand (PD-1/PD-L1) inhibitor.

公开(公告)号：US20180326084A1

公开(公告)日：2018-11-15

申请号：US15742818

申请日：2016-07-08

Applicant: GENMAB A/S

Inventor： Julia BOSHUIZEN ,  Kirstine JACOBSEN ,  Esther BREIJ ,  Louise KOOPMAN ,  David SATIJN ,  Edward VAN DEN BRINK ,  Dennis VERZIJL ,  Rob DE JONG ,  Riemke VAN DIJKHUIZEN RADERSMA ,  Daniel PEEPER ,  Henrik Jørn DITZEL ,  Paul PARREN

IPC: A61K47/68 ,  C07K16/28 ,  A61P35/00 ,  A61K45/06 ,  A61K39/00

CPC classification number: A61K47/6803 ,  A61K39/001102 ,  A61K45/06 ,  A61K47/6801 ,  A61K47/6849 ,  A61K47/6851 ,  A61K47/6855 ,  A61K47/6857 ,  A61K47/6869 ,  A61K2039/505 ,  A61P35/00 ,  C07K16/2863 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/732 ,  C07K2317/77 ,  C07K2317/92

Abstract: The present disclosure relates to antibody-drug conjugates (ADCs) binding to human AXL for therapeutic use, particularly for treatment of resistant or refractory cancers.

公开(公告)号：US20170355767A1

公开(公告)日：2017-12-14

申请号：US15541594

申请日：2016-01-08

Applicant: GENMAB A/S

Inventor： Patrick ENGELBERTS ,  Esther BREIJ ,  Rik RADEMAKER ,  Isil ALTINTAS ,  David SATIJN ,  Sandra VERPLOEGEN ,  Riemke VAN DIJKHUIZEN RADERSMA ,  Edward VAN DEN BRINK ,  Janine SCHUURMAN ,  Paul PARREN

IPC: C07K16/28 ,  A61K39/395

CPC classification number: C07K16/2809 ,  A61K39/39558 ,  A61K2039/505 ,  C07K16/2887 ,  C07K16/30 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/567 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/75 ,  C07K2317/90 ,  C07K2317/92 ,  C07K2317/94

Abstract: Bispecific antibodies directed to CD3 and CD20 and uses of such bispecific antibodies, in particular use thereof in the treatment of diseases in which specific targeting and T cell-mediated killing of cells that express CD20 is desired.